+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Alpha 1 Antitrypsin Deficiency Treatment Market - Global Forecast 2026-2032- Product Image
Alpha 1 Antitrypsin Deficiency Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Alpha 1 Antitrypsin Deficiency Treatment Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5887662
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Alpha 1 Antitrypsin Deficiency Treatment Market is projected to reach USD 3.83 Billion in 2026. It is expected to continue growing at a CAGR of 9.78%, reaching USD 6.79 Billion by 2032.

Alpha-1 antitrypsin deficiency is an inherited disorder that can cause progressive lung disease, liver disease, and, less commonly, skin complications. Treatment strategy depends on genotype, circulating alpha-1 antitrypsin levels, pulmonary function, liver status, smoking and occupational exposure, and the presence of recurrent respiratory infections. Care therefore combines diagnosis, risk-factor reduction, disease monitoring, symptom management, and specialist referral rather than relying on a single intervention.

Earlier Diagnosis and Integrated Care Are Reshaping Treatment

The treatment landscape is shifting toward earlier identification of affected individuals and structured follow-up across pulmonology, hepatology, genetics, primary care, and transplant services. Greater use of confirmatory genotyping and serum-level testing can help distinguish deficiency from common obstructive lung disease and support family testing. At the same time, pulmonary rehabilitation, vaccination, smoking cessation, exposure avoidance, and individualized management of chronic airflow limitation remain central to preserving function and quality of life.

Artificial Intelligence Is Strengthening Detection and Care Coordination

Artificial intelligence can support alpha-1 antitrypsin deficiency care by identifying testing candidates within electronic health records, recognizing imaging and spirometry patterns that warrant specialist review, and helping stratify patients for follow-up. Its practical value depends on representative training data, transparent validation, clinician oversight, and safeguards for genetic and health information. AI should augment-not replace-confirmatory laboratory testing, clinical assessment, and shared decision-making.

Regional Differences Reflect Diagnostic Capacity and Specialist Access

In North America, established specialty networks and genetic testing capacity support diagnosis, although under-recognition and uneven access remain concerns. Europe benefits from coordinated rare-disease frameworks, while variation among countries affects testing pathways and access to specialist services. Asia-Pacific combines advanced centers with substantial gaps in awareness, laboratory capacity, and rural access. In Latin America, referral delays and affordability can limit continuity of care. The Middle East is influenced by hereditary-risk patterns, specialist concentration, and expanding genomic services. Africa faces major challenges in case recognition, confirmatory testing, and access to multidisciplinary respiratory and liver care.

International Groups Can Align Standards and Expand Referral Pathways

Across the ASEAN group, differences in health-system capacity make shared education, referral protocols, and laboratory partnerships especially valuable. BRICS members can advance diagnosis through regional research collaboration and stronger rare-disease infrastructure. The European Union can use cross-border networks and common clinical standards to reduce variation. G7 countries have an opportunity to strengthen evidence generation and equitable access models. Within the GCC, concentrated specialist resources can support regional centers of excellence. NATO members may benefit from interoperable medical education, preparedness, and referral practices, while maintaining civilian-focused clinical governance.

Country Priorities Range from Case-Finding to Specialist Coordination

Australia and Canada can build on specialist services by improving systematic case-finding across dispersed populations. Brazil, Mexico, India, and Russia would benefit from broader clinician awareness, affordable confirmatory testing, and clearer referral pathways. China, Japan, and South Korea have opportunities to integrate genomic diagnostics with respiratory and liver disease programs. France, Germany, Italy, Spain, and the United Kingdom can further reduce diagnostic delay through coordinated rare-disease networks and standardized follow-up. In the United States, continued emphasis on testing in appropriate clinical settings, family evaluation, and longitudinal multidisciplinary care remains important.

Prioritize Earlier Case-Finding, Coordinated Care, and Evidence-Based Access

Industry leaders should support validated testing pathways for patients with unexplained airflow obstruction, emphysema at an atypical age, relevant family history, or compatible liver disease. Investments should focus on clinician education, laboratory quality, genetic counseling, and referral coordination. Care programs should measure diagnostic interval, testing completion, pulmonary-function monitoring, vaccination and smoking-cessation support, treatment persistence, and patient-reported outcomes. Any development of novel or digitally enabled approaches should include clinically meaningful endpoints, transparent evidence, privacy protection, and access planning across high- and lower-resource settings.

Methodology: Evidence-Based Synthesis of Diagnosis, Care, and Regional Context

This executive summary synthesizes established clinical and health-system considerations for alpha-1 antitrypsin deficiency treatment. The assessment organizes evidence around disease biology, diagnostic practice, supportive and specialist care, emerging digital tools, and differences in regional and country-level capacity. It avoids market estimates, forecasts, market shares, and company-specific claims. Regional, group, and country observations are framed as qualitative system-level insights and should be validated against current clinical guidelines, regulatory requirements, epidemiology, and local access data before operational use.

A Coordinated, Earlier-Diagnosis Model Offers the Strongest Path Forward

Alpha-1 antitrypsin deficiency treatment is best advanced through timely recognition, confirmatory testing, prevention of avoidable lung injury, structured monitoring, and integrated pulmonary-liver care. Progress will depend on closing geographic and socioeconomic gaps in diagnosis, strengthening specialist referral systems, and applying artificial intelligence responsibly. Leaders that combine evidence-based clinical pathways with patient education, family evaluation, and measurable quality standards can improve consistency of care without overrelying on any single therapeutic or technological approach.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Therapy Class
7.1. Introduction
7.2. Augmentation Therapy
7.3. Gene Therapy
7.3.1. AAV Vector
7.3.2. Lentiviral Vector
7.4. Plasma Infusion
8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Delivery Mode
8.1. Introduction
8.2. Inhalation
8.3. Intravenous
9. Alpha 1 Antitrypsin Deficiency Treatment Market, by Patient Age Group
9.1. Introduction
9.2. Adults
9.3. Geriatrics
9.4. Pediatrics
10. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Alpha 1 Antitrypsin Deficiency Treatment Market, by End User
11.1. Introduction
11.2. Homecare
11.3. Hospitals
11.4. Specialty Clinics
12. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Alpha 1 Antitrypsin Deficiency Treatment Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Alpha 1 Antitrypsin Deficiency Treatment Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AstraZeneca PLC
16.2. Baxter International Inc.
16.3. Bayer AG
16.4. Biogen Inc.
16.5. Biotest AG
16.6. Boehringer Ingelheim International GmbH
16.7. CSL Behring GmbH
16.8. GlaxoSmithKline plc
16.9. Grifols S.A.
16.10. Kamada Pharmaceuticals
16.11. Takeda Pharmaceutical Company Limited
16.12. Vertex Pharmaceuticals
17. Key Experts
List of Figures
FIGURE 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market, Years Considered for the Study
FIGURE 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market, Research Design
FIGURE 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market, Research Framework
FIGURE 4. Global Alpha 1 Antitrypsin Deficiency Treatment Market, Data Triangulation
FIGURE 5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2025 vs 2032 (%)
FIGURE 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2025 vs 2032 (%)
FIGURE 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 11. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Segmentation & Coverage
TABLE 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 4. Global Augmentation Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Augmentation Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Augmentation Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global AAV Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global AAV Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global AAV Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Lentiviral Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Lentiviral Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Lentiviral Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Plasma Infusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Plasma Infusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Plasma Infusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 20. Global Inhalation Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Inhalation Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Inhalation Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 27. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Geriatrics Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Geriatrics Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Geriatrics Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Pediatrics Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Pediatrics Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Pediatrics Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 37. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 47. Global Homecare Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Homecare Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Homecare Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 64. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 66. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 67. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 68. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 69. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 70. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 73. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 74. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 75. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 76. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 80. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 81. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 82. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 83. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 84. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 85. Middle East Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Middle East Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 87. Middle East Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 88. Middle East Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 89. Middle East Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 90. Middle East Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 91. Middle East Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 92. Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 94. Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 95. Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 96. Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 97. Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 98. Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 102. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 103. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 104. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 105. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 106. ASEAN Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 109. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 110. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 111. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 112. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. GCC Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. European Union Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. European Union Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 116. European Union Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 117. European Union Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 118. European Union Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 119. European Union Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. European Union Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. BRICS Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 122. BRICS Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 123. BRICS Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 124. BRICS Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 125. BRICS Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 126. BRICS Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. BRICS Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. G7 Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. G7 Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 130. G7 Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 131. G7 Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 132. G7 Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 133. G7 Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 134. G7 Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. NATO Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. NATO Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 137. NATO Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 138. NATO Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 139. NATO Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 140. NATO Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. NATO Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 142. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 144. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 145. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 146. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 147. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 148. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 151. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 152. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 153. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 154. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 155. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 156. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 158. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 159. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 160. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 161. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 162. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 163. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 165. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 166. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 167. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 168. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 169. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 172. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 173. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 174. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 175. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 176. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. United Kingdom Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 178. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 179. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 180. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 181. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 182. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 183. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. France Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 186. France Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 187. France Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 188. France Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 189. France Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 190. France Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. France Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 193. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 194. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 195. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 196. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 197. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 200. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 201. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 202. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 203. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 204. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 206. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 207. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 208. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 209. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 210. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 211. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. Spain Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. China Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 214. China Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 215. China Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 216. China Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 217. China Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 218. China Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 219. China Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. India Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 221. India Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 222. India Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 223. India Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 224. India Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 225. India Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. India Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 228. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 229. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 230. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 231. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 232. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 233. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 234. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 235. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 236. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 237. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 238. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 239. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size, 2017-2032 (USD Million)
TABLE 242. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Therapy Class, 2017-2032 (USD Million)
TABLE 243. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 244. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Delivery Mode, 2017-2032 (USD Million)
TABLE 245. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 246. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share, by Key Player, 2025
TABLE 249. Global Alpha 1 Antitrypsin Deficiency Treatment Market, Key Experts

Companies Mentioned

  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Biotest AG
  • Boehringer Ingelheim International GmbH
  • CSL Behring GmbH
  • GlaxoSmithKline plc
  • Grifols S.A.
  • Kamada Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages198
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.83 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.79 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Alpha 1 Antitrypsin Deficiency Treatment - Global Strategic Business Report - Product Image

Alpha 1 Antitrypsin Deficiency Treatment - Global Strategic Business Report

  • Report
  • 184 Pages
  • Global
From
Alpha-1 Antitrypsin Deficiency - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Alpha-1 Antitrypsin Deficiency - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 216 Pages
  • Global
From
Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2026-2034 - Product Image

Alpha 1 Antitrypsin Deficiency Treatment Market Report by Treatment Type, Route of Administration, End User, and Region 2026-2034

  • Report
  • 143 Pages
  • Global
From
Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Analysis Report 2025 - Product Image

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.